Popular Articles

New Mechanism For Amyloid Beta Protein's Toxic Impact On The Alzheimer's Brain
Scientists have uncovered a novel mechanism linking soluble amyloid í² protein with the synaptic injury and memory loss associated with Alzheimer"s disease (AD). The research, published by Cell Press in the June 25 issue of the journal Neuron, provides critical new insight into disease pathogenesis and reveals signaling molecules that may serve as potential additional therapeutic targets for AD.
generic viagra online
Clinipace To Manage Two Phase II Clinical Trials For Inspire Pharmaceuticals
Clinipace, a digital clinical research organization, announced that Inspire Pharmaceuticals, Inc. has selected the company to manage and deploy two phase II studies for the ophthalmic prescription medicine, AzaSite®.
News of the day
Innovative Study Has Brought Us Closer To An Explanation For Crohn's Disease: Research Institute Of The MUHC
Twenty-five per cent of Crohn"s disease patients have a mutation in what is called the NOD2 gene, but it is not precisely known how this mutation influences the disease. The latest study by Dr. Marcel Behr, of the Research Institute of the MUHC and McGill University, has provided new insight into how this might occur. The study was published on July 9th in the Journal of Experimental Medicine.
Mental Health

Finance Committee Seeks To Trim Cost Of Bill

"A draft proposal in the Senate to overhaul the nation"s health-care system would require most people to buy health insurance, authorize an expansion of Medicaid coverage and create consumer-owned cooperative plans instead of the government coverage that President Obama is seeking," the Washington Post reports. The proposal, a preliminary version of legislation being shaped by the Senate Finance Committee, also contained "an array of coverage provisions that were drastically scaled back from earlier versions, as lawmakers seek to shrink the bill"s overall cost." Absent from the blueprint was was a "public option," which "marks perhaps the most significant omission." Obama and many Democrats had sought this option as a means to "expand coverage and reduce costs" but "as many as 10 Senate Democrats have protested the idea as unfair to private insurers. In its place, the draft circulated yesterday outlines a co-op approach modeled after rural electricity and telecom providers, subject to government oversight and funded with federal seed money" (Montgomery and Murray, 6/19). Other coverage of the Finance Committee: Wall Street Journal: "A key Senate committee, pressed to find ways to pay for a health-care expansion, is considering cuts in Medicare that would kick in automatically if other efforts to trim spending in the program fail." Sen. Max Baucus, D-Mont., the Finance chairman, suggested that Congress set a goal for lowering costs, such as by 1.5 percent a year, allowing the Medicare Payment Advisory Commission to implement policy changes that would help achieve that goal after their policies are approved by a yes-no vote in Congress (Meckler and Hitt, 6/19). Bloomberg: "U.S. senators seeking to lower the price tag of a health-care overhaul below a $1.6 trillion estimate are cutting back proposed subsidies to help low-income Americans buy insurance." Senators had earlier proposed subsidies to buy insurance for people making 400 percent of the poverty line or less. The new plan would only help individuals and families make 300 percent of the poverty line, or less (Litvan and Ronmoyer, 6/19). CongressDaily: The committee is also "weighing an alternative to an employer mandate to provide health insurance that would instead require a contribution on businesses" part if their employees participate in either Medicaid or an [health insurance] exchange." Under the alternative plan, "an employer would not have to provide healthcare coverage for their employees but would be forced to contribute the cost of tax credits for eligible workers in an exchange" (Edney, 6/19). A second CongressDaily story about progress in the HELP Committee notes that "still missing are the most controversial pieces of the bill: an outline for a public plan, a possible employer mandate and language dealing with generic biologic drugs. [Sen. Christopher] Dodd [D-Conn.] said he expected to release those details "probably in the next couple of days." He had previously said Republicans would receive the language by today so they could submit amendments by Monday" (Hunt, 6/19). This information was reprinted from kaiserhealthnews.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives and sign up for email delivery at kaiserhealthnews.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):